Assessing the Quality of Serological Testing in the COVID-19 Pandemic: Results of a European External Quality Assessment (EQA) Scheme for Anti-SARS-CoV-2 Antibody Detection-Reference-Cited by-同舟云学术

Assessing the Quality of Serological Testing in the COVID-19 Pandemic: Results of a European External Quality Assessment (EQA) Scheme for Anti-SARS-CoV-2 Antibody Detection

Published:2021-08-18 Issue:9 Volume:59 Page:
ISSN:0095-1137
Container-title:Journal of Clinical Microbiology
language:en
Short-container-title:J Clin Microbiol

Author:

Ast Volker¹,Costina Victor¹,Eichner Romy¹,Bode Anna²,Aida Sihem¹,Gerhards Catharina¹,Thiaucourt Margot¹,Dobler Gerhard³⁴,Geilenkeuser Wolf-Jochen²,Wölfel Roman³⁴,Neumaier Michael¹,Haselmann Verena¹^ORCID

Affiliation:

1. Department of Clinical Chemistry, University Medical Centre Mannheim, Medical Faculty Mannheim of the University of Heidelberg, Mannheim, Germany

2. Reference-Institute for Bioanalytics, German Society for Clinical Chemistry and Laboratory Medicine (DGKL), Bonn, Germany

3. Bundeswehr Institute of Microbiology, Munich, Germany

4. German Center for Infection Research (DZIF), Partner Site Munich, Germany

Abstract

External quality assessment (EQA) is a key instrument for achieving harmonization, and thus a high quality, of diagnostic procedures. As reliable test results are crucial for accurate assessment of SARS-CoV-2 infection prevalence, vaccine response, and immunity, and thus for successful management of the ongoing COVID-19 pandemic, the Reference Institute for Bioanalytics (RfB) was the first EQA provider to offer an open scheme for anti-SARS-CoV-2 antibody detection.

Publisher

American Society for Microbiology

Subject

Microbiology (medical)

Link

https://journals.asm.org/doi/pdf/10.1128/JCM.00559-21

Reference38 articles.

1. U.S. Food & Drug Administration. Emergency use authorization. in vitro diagnostic products. https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization.

2. European Commission. COVID-19 in vitro diagnostic devices and test methods database. https://covid-19-diagnostics.jrc.ec.europa.eu/devices?manufacturer&text_name&marking&rapid_diag&format&target_type&field-1=Assay%20category&value-1=3&field-2=Assay%20category&value-2=4&search_method=OR#form_content.

3. U.S. Food & Drug Administration. Insight into FDA’s revised policy on antibody tests: prioritizing access and accuracy. https://www.fda.gov/news-events/fda-voices/insight-fdas-revised-policy-antibody-tests-prioritizing-access-and-accuracy.

4. U.S. Food & Drug Administration. EUA authorized serology test performance. https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance.

5. Comparison of test performance of commercial anti-SARS-CoV-2 immunoassays in serum and plasma samples

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical and laboratory considerations: determining an antibody-based composite correlate of risk for reinfection with SARS-CoV-2 or severe COVID-19;Frontiers in Public Health;2023-12-28

2. A Prototype Assay Multiplexing SARS-CoV-2 3CL-Protease and Angiotensin-Converting Enzyme 2 for Saliva-Based Diagnostics in COVID-19;Biosensors;2023-06-27

3. Subsequent COVID-19 Prophylaxis in COVID-19 Associated Glomerulopathies;Vaccines;2023-06-26

4. Three rounds of a national external quality assessment reveal a link between disharmonic anti-SARS-CoV-2 antibody quantifications and the infection stage;Clinical Chemistry and Laboratory Medicine (CCLM);2023-02-10

5. Real-world performance of SARS-Cov-2 serology tests in the United States, 2020;PLOS ONE;2023-02-03